ARCHIVES

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

Upton Prefers Keeping Bioassay Program In NCI

May 12, 1978

Impeding Reagan Budget Cuts Feared By Cancer Program Advocates; DeVita Asks Parity With NIH

February 13, 1981

DCBDC Bard Approves Expansion Of SPORE Program To GY Cancers; Okays Two other RFAs

December 4, 1992

GAO Study Claiming No Benefit Seen In Adjuvant Breast Cancer Treatment Flawed, NCI Responds

April 21, 1989

New Risk Stratification Method For Prostate Cancer Described

November 28, 2003

DCT Advisors Approve Recompetition Of Drug Discovery Groups

June 23, 1995